Completed NA INTERVENTIONAL 2-arm NCT05470166

Lidocaine Infusion With ERAS Protocol for Pancreatic Cancer Surgery: Effect on Pain and Patient Immunity. (ERAS)

Lidocaine Infusion With Enhanced Recovery Program for Pancreatic Cancer Surgery: Effect on Pain and Patient Immunity

Sponsor: Alexandria University

Conditions Cancer of Pancreas ERAS Lidocaine Natural Killer Cell Cytokine Production

Updated 4 times since 2022 Last updated: Aug 19, 2024 Started: Apr 20, 2022 Primary completion: Jan 17, 2024 Completion: Apr 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05470166, this NA trial focuses on Cancer of Pancreas and ERAS and remains completed. Sponsored by Alexandria University, it has been updated 4 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed NA

Status: Unknown → Completed
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
May 2024 — Jul 2024 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Sep 2022 — May 2024 [monthly]

Recruiting NA

First recorded

Apr 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alexandria University
University of Alexandria

Data source: Alexandria University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Alexandria, Egypt